Development and field evaluation of a rapid detection method for Babesia microti using fluorescent recombinase polymerase amplification(RPA) technology Authors: Yuchun Cai, Han Yin Yang, Kun Qiang, Chenghang Yu, Shuning Yan, Ziran Mo, Bin Zheng, Bin Xu, Wei Hu Published: 2026 ABSTRACT AbstractThe frequent occurrences of Babesia microti (B. microti) infection have emerged as a significant global public health safety concern. The diagnosis of patients constitutes a crucial component in the prevention and control of babesiosis, necessitating the urgent establishment of efficient and accurate molecular biology diagnostic methods for B. microti detection. This study aimed to develop a sensitive, specific, and rapid fluorescent recombinase polymerase amplification (RPA) technique for the detection of B. microti (B. microti) and assess its suitability for field use. This study developed and optimized a fluorescent RPA assay targeting the B. microti 18 S rRNA gene fragment. The method’s sensitivity (detection limit down to 10 fg/µL genomic DNA), specificity (distinguishing Plasmodium samples), and detection limit for spiked mouse blood samples (across varying parasitemia levels) were evaluated. The detection capability was validated using samples from an infected mouse model (tail-tip blood collected 3–21 days post-infection) and two confirmed human cases. Furthermore, 119 blood samples from patients presenting with fever accompanied by thrombocytopenia were tested using both nested PCR and the newly developed fluorescent RPA assay. The agreement between the two methods was analyzed using the Kappa value, and the significance of their difference was assessed using McNemar’s test. A fluorescent RPA assay was developed targeting two B. microti 18 S rRNA fragments (243 bp/191 bp). The 191 bp fragment demonstrated superior sensitivity (detection limit: 1 fg/µL genomic DNA) and was selected for assay establishment. Optimized at 39 °C for 20 min, its detection threshold was defined by the lowest detectable concentration (1 fg/µL). Specificity testing with 8 P. falciparum and 8 P. ovale samples showed fluorescence below this threshold. The assay achieved a detection limit of 0.046 parasites/µL blood, demonstrating a 600-fold increase in sensitivity compared to nested PCR, which detects 28.49 parasites/µL. In infected mice, both RPA and nested PCR detected parasites by day 9 post-infection (microscopy: day 15), with RPA showing higher positivity. The method confirmed infection in 2 patients. Among 119 febrile patients with thrombocytopenia from Xinyang City, Henan Province, nested PCR detected 20 B. microti-positive cases while fluorescent RPA detected 21. The Kappa value for agreement between the methods was 97.05% (91.31% − 100%), and McNemar’s test indicated no statistically significant difference in their detection rates (S = 1, P > 0.1). Based on the combined results of both tests, the molecular positivity rate for B. microti in this sample set was 17.65%, with co-infections involving Bunya virus present, accounting for 10.08% of the tested samples. The fluorescence RPA method provides a rapid, sensitive, and specific tool for detecting B. microti and is effective for field screening.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-42288-3.Keywords: Babesiosis, Babesia microti, Recombinase polymerase amplification, Fluorescence RPA technologySubject terms: Biological techniques, Biotechnology, Diseases, Microbiology, Molecular biology Introduction Babesiosis is a parasitic zoonosis caused by infection with Babesia (Babesia spp.) species. The definitive hosts of Babesia’s are various species of ticks, while the intermediate hosts are primarily mammals, including cattle, dogs, and sheep. Humans can also serve as intermediate hosts1–4. Within the intermediate host, Babesia infects erythrocytes, where it exists as trophozoites and merozoites5,6. The incubation period following infection is generally prolonged, often lasting more than a week, with fever and anemia being the predominant symptoms4,7. B. microti and Babesia venatorum are the most common species reported in China, with hundreds of confirmed cases8. Most B. venatorum, cases have been found in Northeast China, while B. microti infections have been reported in southern provinces, including Yunnan, Guangxi, and Fujian8,9. Molecular screening for Babesia has revealed more than 100 positive cases in studies of patients with fever or tick bites8. Although only about 320 cases of Babesia infections are reported in China, prioritizing prevention, control, and rapid diagnosis is critical8. The early symptoms of Babesia microti infection, such as fever and fatigue, are easily confused with malaria or other febrile illnesses. Highly sensitive diagnostic tests enable rapid confirmation during the low parasitemia stage, preventing treatment delays that may lead to severe complications (e.g., hemolytic anemia, organ failure) or even death10. B. microti is a zoonotic pathogen. Highly sensitive detection technologies (such as fluorescent recombinase polymerase amplification (RPA)) can accurately identify asymptomatic carriers and low-level infections in environmental or reservoir animal hosts, providing crucial data for epidemic early warning11. High-sensitivity testing is vital for ensuring transfusion safety risks, as the blood of asymptomatic infected individuals can transmit babesiosis via transfusion. The US FDA mandates nucleic acid testing (NAT) for blood donor screening, requiring a sensitivity capable of detecting 1–10 parasites/µL (≈ 1 fg/µL DNA) to interrupt the transfusion transmission chain12. Molecular detection methods for Babesia spp. include conventional PCR, real-time quantitative PCR (qPCR), loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA). These techniques amplify pathogen nucleic acids by targeting specific genes (e.g., 18 S rRNA, mitochondrial genes, or heat shock protein genes), ensuring high sensitivity and specificity. Compared to conventional PCR, RPA amplifies nucleic acid in just 20 min without the need for a thermal cycler, making it highly suitable for field or clinic use. While both methods exhibit comparable sensitivity (detecting 1ཞ10 copies), RPA demonstrates superior stability in low-concentration samples. In contrast to LAMP, RPA offers distinct advantages: faster reaction times, simplified primer design, and lower temperature requirements (37ཞ42°C)13, enhancing its applicability in resource-limited settings. Key benefits of RPA for Babesia spp detection include its capacity to diagnose low-parasitemia infections14, rapid diagnosis15, field applicability through portable fluorescence detectors16, and the ability to multiplex detect of species such as B. microti and B. venatorum using multicolor probe design. This study aims to establish a sensitive, specific, efficient, and rapid fluorescent recombinase polymerase amplification (RPA) assay for the detection of B. microti and to evaluate its diagnostic value through laboratory assessment and field sample testing. Methods Sample collection The standard B. microti Peabodymjr strain (ATCC, RPA-99) was purchased from the American Type Culture Collection (Manassas, VA) and maintained in BALB/c mice via serial passages, following previously described methods17. All animal experiments conducted in this study were approved by the Experimental Animal Welfare and Ethics Committee of the Animal Center of the Institute of Parasitic Disease Prevention and Control and the Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research) (Animal Ethics Approval No: IPD-2019-14). Blood samples from patients infected with P. falciparum and P. ovale were collected and preserved by the same institute. Blood samples from healthy donors were provided by the Health Examination Center of Shanghai, China. While samples from B. microti infected patients were provided by the Zhejiang Provincial Center for Disease Control and Prevention. Samples from patients with fever and thrombocytopenia were collected and provided by the Henan Provincial Center for Disease Control and Prevention. Ethics statement The animal and human blood collection study was reviewed and approved by The Laboratory Animal Welfare & Ethics Committee (LAWEC) of the Chinese Centre for Tropical Diseases Research (permit Number: IPD-2019-14) and the Medical Ethics Committee of National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research) (Ethical approval number 2019004). All methods were carried out in accordance with relevant guidelines and regulations. The informed consent was obtained from all subjects and/or their legal guardian(s). Establishment of the fluorescence RPA method Design primers for RPA detection of B. microti Primers were designed for the 18S rRNA, regions of B. microti. According to RPA primer design principles, RPA method primers are typically longer than conventional PCR primers but are generally designed between 27–35 bp to avoid dimer formation caused by excessive length. Additionally, the CG base content at both ends of the primer should be optimized. Specifically, excessive clustering of G bases at the 5’-end should be avoided, while the CG ratio at the 3’-end should be increased to enhance amplification efficiency. Using Primer Premier 6.0 and DNAMAN, along with manual design, six sets of primers were generated (Supplementary Table 1). Design primers and probes for fluorescence RPA detection of B. microti Based on the RPA amplification results, primers and probes for fluorescent RPA were designed for the fragments corresponding to the better-performing primer groups 2 and 7. To identify the optimal primers and probe for B. microti fluorescent RPA, two pairs of primers (27–35 bp in length) and a probe (modified with a tetrahydrofuran [THF] site and labeled with a FAM fluorophore at the 5′end) were designed for each of the two selected fragments (groups 2 and 7), resulting in three candidate pairs per group (e.g., 2 − 1, 2–2, 2–3;7 − 1, 7 − 2, 7 − 3). Screening was conducted using B. microti genomic DNA as the template under the following conditions: 39 °C for 40 min. The optimal primers and probe were determined by comparing the fluorescence intensity curves generated during the reaction. The sequences of the selected primers and probes are shown in Table 1. Table 1Primers and probes of fluorescent recombinase polymerase amplification (RPA) method.Accession numberNumberPrimer and probe sequences(5’→3’)Primer and probe namesMK609547.12CACAGGGAGGTAGTGACAAGAAATAACAAT2-1-FTATT GGAGCTGGAATTACCGCGGCTGCT2-1-RCTTCCCAGAGTATCAATTGGAGGGCAAGTC2-2-FCAAGGCAGAAATTCAACTACGAGCTTCTTAAC2-2-RCAGGGCTTAAAGTCTTGTAATTGGAATGATG2-3-FGACTTG CCCTCCAATTGATACTCTGGGAAGG2-3-RCTTCTTAACTGCAACAACTTTAATATACGC/i6FAMdT//idSp//iBHQdT/TGGAGCTGGAATTAC-C3 Spacer2-PROBE7TTCGATTCCGGAGAGGGAGCCTGAGAAACG7-1-FCTGCAACAACTTTAATATACGCTATTGGAG7-1-RCTGAGAAACGGCTACCACATCTAAGGAAGGC7-2-FCTGCTGGCACCAGACTTGCCCTCCAATTGA7-2-RCGGCTACCACATCTAAGGAAGGCAGCAGGC7-3-FTCCCATCATTCCAATTACAAGACTTTAAGC7-3-RCGCAAATTACCCAATCCTGACACAGGGAGG/i6FAMdT//idSp/G/iBHQdT/GACAAGAAATAAC-C3 Spacer7-PROBE Primers and probes of fluorescent recombinase polymerase amplification (RPA) method. DNA extraction the DNA was extracted from blood samples using a blood & tissue nucleic acid extraction kit (Qiagen Company, Germany), according to the manufacturer’s instructions. The extracted DNA was eluted in 50 µL of AE elution buffer and stored at -20 °C until use. DNA concentration and purity were assessed using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). Establishment of a fluorescent RPA reaction system The fluorescent RPA reaction was prepared in a 50 µL reaction volume following the TwistAmp exo Kits (T’wistDx, Cambridge, UK) protocol. The reaction mixture included 2.1 µL each of forward and reverse primers (10 µmol/µL), 0.6 µL fluorescent probe (10 µmol/µL), 25 µL buffer, and 15.2 µL deionized water. After gentle mixing and centrifugation, the solution was transferred to a lyophilized pellet tube, aliquoted into a BIO-RAD eight-tube strip (TLS0851), and briefly centrifuged to remove bubbles. Subsequently, 2 µL DNA template and 3 µL magnesium acetate (280 mmol/L) were added to the tube cap and centrifuged. The reaction was incubated at 39 °C for 4 min in a metal bath, inverted repeatedly for homogenization, and briefly centrifuged. The reaction was performed utilizing a CFX96 fluorescence quantitative PCR instrument (Bio-Rad, USA) at 39 °C for 40 cycles (60 s per cycle, total 40 min). Optimization of temperature and time parameters, and sensitivity evaluation for fluorescent RPA To optimize the temperature, nucleic acid amplification were performed at various temperatures (37℃, 38℃, 39℃, 40℃, 41℃, and 42℃) to determine the optimal conditions for the reaction using the genomic DNA of B. microti as a template. Sensitivity was evaluated by diluting B. microti genomic DNA into eight concentrations: 1 ng/µL, 100 pg/µL, 10 pg/µL, 1 pg/µL, 100 fg/µL, 10 fg/µL, 1 fg/µL, and 0.1 fg/µL, blank controls were double distilled water. Fluorescence RPA reactions were initially set for 40 min and monitored. At 20 min, clear amplification was observed for the 1 fg/µL group, allowing for the reduction of reaction time. Subsequent testing was conducted for 20 min to assess the method’s performance within this time frame. Parallel nested PCR was performed using the same samples. The nucleotide sequence of the 18 S rRNA-specific fragment was amplified using the extracted DNA as the template, with primers listed in supplementary Table 2, according to the previously described protocols18. Laboratory evaluation of the fluorescent RPA method Specificity evaluation of the fluorescent RPA method To evaluate the specificity of the method, fluorescent RPA reactions were performed using blood samples from 8 patients infected with Plasmodium falciparum and 8 patients infected with Plasmodium ovale. Patient samples served as positive controls, B.microti genomic DNA concentrations of 1 fg/µL were used as the threshold reference, and samples from healthy individuals were included as negative controls. The specificity of the method was assessed by observing the fluorescence intensity of each reaction group. Determination of the parasite density minimum detection limit for fluorescent RPA Female Balb/c mice infected with the ATCC, RPA-99 strain of B. microti were used. Blood was collected from the orbital sinus of infected Balb/c mice (with a microscopically confirmed parasite density of 4%) into EDTA anticoagulant tubes and thoroughly mixed. Blood from uninfected mice was collected and anticoagulated using the same method. A 20 µL aliquot of B. microti-infected blood was diluted 5-fold with 80 µL of normal mice blood, resulting in an initial parasite density of 445,200 parasites /µL. A total of 14 dilution groups were prepared, with the lowest parasite density reaching 0.00037 parasites /µL. DNA was extracted from each diluted blood sample. The established fluorescent RPA detection method for B. microti was applied to detect the samples, using 2 µL of template DNA from each of the 14 diluted blood groups. Normal mice blood DNA served as negative controls. To evaluate the performance of the fluorescent RPA method in detecting B. microti DNA in blood, nested PCR was implemented as a parallel control. The minimum detection limit of nested PCR for B. microti DNA in the 14 blood groups was determined by observing agarose gel electrophoresis results. This limit was then compared with that of the fluorescent RPA method. Detection of B. microti in an infected mouse model Mice were infected with B. microti using an inoculum lower than the minimum detection limit of nested PCR to create a low-infection-rate animal model. Blood was collected from the tail tip of the mice on days 3, 6, 9, 12, 15, 18, and 21 post-infection. Thin blood smears were prepared, and samples were stained with Giemsa, The number of infected cells per 1000 red blood cells was counted. The infection rate was then calculated using the same method according to scribed protocols19. Three slides were observed for each group. DNA was extracted for subsequent testing. Nested PCR and fluorescence RPA detection were performed until all mice tested positive. Detection rates were determined by recording the time at which positive results were first obtained through nested PCR, fluorescence RPA, and microscopy. The number of positive mice identified by each method was recorded at each time point. Detecting of B. microti in clinical patients using fluorescent RPA method To assess the diagnostic accuracy of the established fluorescent RPA method for confirmed B. microti infections, blood samples from two microscopy-positive patients in Zhejiang Province were analyzed. Molecular detection was initially performed using touchdown PCR with the genus-specific primers BJ1 (5’-GTCTTGTAATTGGAATGATGG-3’) and BN2 (5’-TAGTTTATGGTTAGGACTACG-3’). The 50 µL reaction mixture comprised 25 µL of PCR mix (2× Taq PCR MasterMix (Tiangen Biotech, Beijing, China)), 22 µL of deionized water, 1 µL each of forward and reverse primers (10 µmol/µL), and 1 µL of DNA template. Thermal cycling conditions included an initial denaturation at 96 °C for 6 min, followed by 8 cycles of 95 °C for 30 s, 58 °C for 45 s, and 70 °C for 1 min (with annealing temperature decreasing by 1 °C per cycle), then 27 cycles of 95 °C for 30 s, 50 °C for 45 s, and 70 °C for 1 min, and a final extension at 70 °C for 8 min. Samples positive for Babesia genus amplification were sequenced and validated via BLAST analysis. Subsequent nested PCR and the fluorescent RPA method were applied to detect B. microti. Controls included B.microti genomic DNA (positive control), healthy human blood (negative control), and deionized water (blank control) to ensure assay specificity and reliability. Field application of fluorescence RPA Based on cases reported in 2012 in Xinyang, Henan Province, there were instances of patients presenting with fever and thrombocytopenia who were co-infected with Babesia parasites20, This study employed the fluorescence RPA method to test blood samples from 119 patients with fever and thrombocytopenia collected by the Henan Provincial Center for Disease Control and Prevention in 2015,.Controls included B.microti genomic DNA (positive control), healthy human blood (negative control), detect threshold concentration (1 fg/µL) in order to evaluate its effectiveness for field use. Data analysis Data analysis was conducted using SAS 9.4. Detection rates and Kappa values of fluorescence RPA and nested PCR were compared, and the McNemar test was used to determine significant differences between the two methods. To enhance detection sensitivity, a combined testing approach was employed to determine B. microti infection in samples. A sample was classified as B. microti-positive if either method yielded a positive result. This outcome was then cross-referenced with the previously investigated Bunyavirus infection status of the samples to assess co-infection patterns between the two pathogens. Results Establishment of the fluorescence RPA method Screening of the RPA primers In this study, target sequences were screened from the18S rRNA gene of B. microti. BLAST analysis identified 7 sequence groups with high interspecies specificity. PCR primers were constructed for fragment screening. As shown in Supplementary Fig. 1A, all but the fifth primer group targeting 18 S rRNA produced a single, distinct band. RPA amplification primers were designed for six primer groups-1st, 2nd, 3rd, 4th, 6th, 7th-which produced favorable PCR results. The amplified products were electrophoresed on agarose gel, as shown in Supplementary Figs. 1B. The 2nd, 7th, primer groups yielded clear, distinct bands. Optimization of RPA fluorescence primers and probes Based on RPA primer design principles, two pairs of primers were created for each of the positively amplified fragments (2, 7) from basic RPA screening. Primer optimization tests conducted for each fragment group. Fluorescence RPA results (Supplementary Fig. 2) showed that none of the primers for fragment 2 produced effective fluorescence curves. Among the three sets of primers for fragment 7, the first pair (7-1-F/7-1-R) generated the highest fluorescence intensity and an earlier peak time, making it the best choice for this fragment. Fluorescence RPA temperature optimization To optimize the reaction temperature, B. microti genomic DNA was amplified at six different temperatures using group 7 sequences 7: 37 °C, 38 °C, 39 °C, 40 °C, 41 °C, and 42 °C. The results (Supplementary Fig. 3) indicated that 39 °C was the optimal temperature for the 7th group sequences, as this temperature produced the highest fluorescence intensity. Thus, 39 °C was chosen as the ideal reaction temperature for subsequent experiments. Fluorescence RPA sensitivity experiment To determine the minimal detection limit and optimal time for fluorescence RPA, reactions were performed with serially diluted B. microti genomic DNA. The results (Fig. 1A) from a 40-minute reaction showed that the assay could detect genomic DNA at a concentration as low as 1 fg/µL, with clear amplification observed for this concentration by 20 min. A subsequent sensitivity test with a fixed 20-minute reaction time confirmed the detection limit of 1 fg/µL (Fig. 1C). In parallel, nested PCR performed on the same dilution series had a lowest detectable concentration of 10 fg/µL (Fig. 1D), but no bands were observed at lower concentrations. Sensitivity detection of the fluorescence RPA and nested PCR methods. (A) Curves 1–8 represent the amplification profile of B. microti genomic DNA diluted in deionized water at a concentration of 1 ng/µL, 100 pg/µL, 10 pg/µL, 1 pg/µL, 100 fg/µL, 10 fg/µL, 1 fg/µL and 0.1 fg/µL, respectively, primers and fluorescent probes designed based on the 18 S rRNA sequences of Group 7. Curve 9 represents the amplification profile of the negative sample. (B) Curves 1–8 represent the amplification profile of B. microti genomic DNA diluted in deionized water at a concentration of 1 ng/µL, 100 pg/µL, 10 pg/µL, 1 pg/µL, 100 fg/µL, 10 fg/µL, 1 fg/µL and 0.1 fg/µL, respectively, primers and fluorescent probes designed based on the 18 S rRNA sequences of Group 8, curve 9 represents the amplification profile of the negative sample. (C) Curves 1–8 represent the amplification profile of B. microti genomic DNA diluted in deionized water at a concentration of 1 ng/µL, 100 pg/µL, 10 pg/µL, 1 pg/µL, 100 fg/µL, 10 fg/µL, 1 fg/µL and 0.1 fg/µL, respectively, primers and fluorescent probes designed based on the 18 S rRNA sequences of Group 7. Curve 9 represents the amplification profile of the negative sample. (D) 1–8 represent the nested PCR results of B. microti genomic DNA diluted in deionized water at a concentration of 1 ng/µL, 100 pg/µL, 10 pg/µL, 1 pg/µL, 100 fg/µL, 10 fg/µL, 1 fg/µL and 0.1 fg/µL, respectively. H represents the negativesample. M represents the DNA marker. Full-length gel of part D was included in a Supplementary Information file. Evaluation of fluorescence RPA detection method for B. microti Specificity of fluorescence RPA Samples from 8 P. falciparum and 8 P. ovale patients showed no peaks, with fluorescence intensities far below the threshold set for B.microti genomic DNA concentrations of 1 fg/µl (Supplementary Fig. 4). Determination of the parasite density minimum detection limit for fluorescent RPA The temporal detection sensitivity of microscopy, nested PCR, and fluorescent RPA was compared in a mouse infection model. Fluorescence RPA detection was simultaneously performed on 14 sets of Balb/c mouse blood samples with varying parasite densities (Supplementary Table 3). The results (Fig. 2A) showed that this method could detect a minimum parasite load of 0.046 B. microti per microliter (µl) of blood. Blood samples from the three groups with even lower parasite densities showed no amplification curve (similar fluorescence intensity to the negative control). Among the positively detected groups, samples with higher parasite densities exhibited higher fluorescence intensities. Nested PCR detection results (Fig. 2B) revealed clear bands in samples with B. microti loads of 445,200, 89,040, 17,808, and 3,561.6 per µl of mouse blood. Samples with loads of 712.32, 142.46, and 28.49 showed faint bands, while no bands were visible in the remaining groups. Therefore, the nested PCR method was able to effectively detect a minimum B. microti load of 28.49 parasites per µl of blood. B. microti density test of fluorescence RPA and nested PCR. (A) Curves 1–14 represent the amplification profile of B. microti genomic DNA from the blood samples from different B. microti densities, - represent the negative reference. (B) Curves 1–8 represent the nested PCR results of B. microti genomic DNA from the blood samples from different B. microti densities, - represent the negative reference. Full-length gel of part B was included in a Supplementary Information file. the parasitemia concentrations of Babesia microti for Samples 1 to 14 are as follows: Sample 1: 445,200 parasites/µl, Sample 2: 89,040 parasites/µl, Sample 3: 17,808 parasites/µl, Sample 4: 3,561.6 parasites/µl, Sample 5: 712.32 parasites/µl, Sample 6: 142.46 parasites/µl, Sample 7: 28.49 parasites/µl, Sample 8: 5.7 parasites/µl, Sample 9: 1.14 parasites/µl, Sample 10: 0.23 parasites/µl, Sample 11: 0.046 parasites/µl, Sample 12: 0.0092 parasites/µl, Sample 13: 0.0018 parasites/µl, Sample 14: 3.7 × 10⁻⁴ parasites/µl. Evaluation of different methods for detecting B. microti in infected mouse models Starting on 3 dpi (day 3 post-infection, shortened to 3 dpi)), 10 mice were tested every 3 days using thin blood film smears and microscopic examination. B. microti was not observed in blood smears from any of the 10 mice on 3 dpi, 6 dpi, 9 dpi, or 12 dpi. On 15 dpi, B. microti was observed in 2 blood smears, and by 18 dpi, 8 samples were positive. By 21 dpi, all samples were positive (Table 2). Nested PCR was performed concurrently, with no bands observed on 3 dpi and 6 dpi. On 9 dpi, a band was detected in one blood sample, and by 12 dpi, 7 samples tested positive. By 15dpi, B. microti was detectable in all 10 mice (Supplementary Fig. 5). No upward fluorescence curve was observed in the blood samples of mice on 3 dpi and 6 dpi after fluorescent RPA amplification, with their fluorescence intensity being close to that of the negative control (Fig. 3A). By 9 dpi, four positive samples were detected (Fig. 3B). On 12 dpi, all blood samples from the 10 mice exhibited fluorescence intensity exceeding 200 RFU after isothermal amplification (Fig. 3C). It is suggested that effective detection of B. microti infection at low density can be achieved in all mice by fluorescent RPA method on 12 dpi. Table 2Infection status of the mice inoculated with B. microti.Dpi(Days of post infection)Microscopy(No. positive / No. tested)nested PCR(No. positive / No. tested)RPA(No. positive / No. tested)3---6---9-+(1/10)+(4/10)12-+(7/10)+(10/10)15+(2/10)+(10/10)+(10/10)18+(8/10)+(10/10)+(10/10)21+(10/10)+(10/10)+(10/10) Infection status of the mice inoculated with B. microti. Fluorescence RPA Results of B. microti infected in mouse models of post infection days. (A) Curves 1–10 represent fluorescence RPA Results of 6 dpi. All samples were negative. + represents the fluorescence threshold. - represents the negative control. (B) Curves 1–10 represent fluorescence RPA results of 9 dpi, samples of No.2, No.5, No.7, No. 9 were positive, and the other ones were negative. + represents the fluorescence threshold. – represents the negative control. (C) Curves 1–10 represent fluorescence RPA results of 12 dpi, all samples were positive. + represents the fluorescence threshold. – represents the negative control. Detecting of B. microti in clinical patients using fluorescent RPA method The nested PCR detection was performed on two patient samples, and both samples tested positive (Fig. 4A).The fluorescence RPA method established in this study was used to detect blood samples from two patients infected with B. microti. Positive controls were genomic DNA from B. microti, and negative controls were blood samples from health individuals and the blank control was water. Both patient samples showed clear peaks with fluorescence intensities exceeding 1000 RFU (Fig. 4B). Detecting of B. microti in Clinical Patients Using Fluorescent RPA Method. (A) Results of patients with B. microti by nest PCR.1–2 the patients with B. microti, + the positive control, - The negative control, M DNA makers. (B) The amplification profile of B. microti genomic DNA from the blood samples of patients infected and the controls. Curves 1 and 2 represent the patients with B. microti in Zhejiang Province, + represents the positive control, - represents the negative control, H represents the blank control. Full-length gel of part A was included in a Supplementary Information file. Preliminary application of the fluorescence RPA method Babesia primers were used in nested PCR amplification of the 119 blood samples from patients with fever and thrombocytopenia.According to the Henan Provincial Center for Disease Control and Prevention, 71 of the 119 patients tested positive for Bunya virus and 48 tested negatives. The products were analyzed using electrophoresis and automated gel imaging. The nested PCR method detected target bands in 20 of 119 blood samples, while the fluorescence RPA method identified B. microti in 21 samples(Supplementary Fig. 6). Thus, the positive rate for B. microti was 17.65% by fluorescence RPA and 16.81% by nested PCR. The Kappa value between the two methods was 97.05% (91.31%-100%), with no significant difference in results (S = 1, P > 0.1). In addition, according to the test results of the combined experiment of the above two methods (a positive test result of one method was considered as positive for B. microti), 12 patients were infected with both pathogens (10.08%), 9 patients were infected with B. microti alone (7.56%), 59 patients were infected with Bunya virus alone (49.58%) and 39 patients were negative for both pathogens (32.77%). The infection status of the two pathogens is shown in Table 3. Table 3Pathogen infection in patients with fever with thrombocytopenia in Xinyang City, Henan Province, 2015.PathogenB. microti positive B. microti negativetotalBunyavirus positive125971Bunyavirus negative93948Total2198119 Pathogen infection in patients with fever with thrombocytopenia in Xinyang City, Henan Province, 2015. Discussion Babesiosis is a parasitic disease transmitted primarily through tick bites. Transfusion-transmitted babesiosis poses a significant threat to blood product safety, particularly in endemic regions. Asymptomatic B. microti infections in donors can evade conventional screening methods, leading to documented cases of transfusion-associated transmission with severe outcomes in immunocompromised recipients12,21. Current FDA recommendations emphasize enhanced screening in high-risk areas, yet limitations persist: serological assays exhibit delayed seroconversion during the window period (> 20% false negatives), while etiological testing remains time-consuming and facility-dependent22. These constraints underscore an urgent need for highly sensitive, rapid point-of-need diagnostics to ensure timely pathogen interception. Rapid detection of B. microti in blood is of great significance for patient treatment and the prevention of Babesia transmission through blood transfusions23. In this study, we successfully developed a fluorescent RPA assay for the detection of B. microti based on the 18s rRNA gene, the detection technology established for B. microti in this study offers greater convenience and efficiency compared to traditional microscopy, requiring less technical expertise. Furthermore, compared to nested PCR technology24,25, a widely used molecular detection method, our method significantly shortens detection time while maintaining high sensitivity. The effective diagnostic sensitivity of this test is demonstrated at 1 fg/µL, which surpasses the 10 fg/µL limit achieved by nested PCR. A study by Wu Fen26 used LAMP to establish a detection technique for B. microti, with a slightly higher sensitivity (0.687 fg/µL) than our RPA method. However, LAMP requires an hour for detection, whereas our method reduces the detection time to just 20 min, offering a distinct advantage in terms of efficiency. Our method proved effective for detecting low parasite densities. For comparison, a study by Nie et al.27 developed a combined flow chromatography and recombinant enzyme RPA method. The results can be determined by observing whether the test strips produce bands. The minimum detection density of this method is 0.5 B. microti per microliter of blood27, but our method demonstrated higher sensitivity. The insidious transmission of B. microti driven by subclinical parasitemia (often < 100 parasites/µL) poses a critical public health challenge. Asymptomatic carriers with persistent low-level infections—undetectable by conventional microscopy or serology—can unknowingly donate contaminated blood, leading to transfusion-transmitted babesiosis (TTB) with mortality rates exceeding 20% in splenectomized or immunocompromised recipients21. Surveillance data indicate that > 80% of TTB cases originate from donations by asymptomatic individuals with parasite densities below microscopic detection limits (≈ 500 parasites/µL), while standard PCR fails to reliably identify burdens < 10 parasites/µL12,23. This diagnostic void perpetuates silent transmission chains, particularly in endemic regions like the northeastern United States and China’s Henan Province, where co-circulation with other tick-borne pathogens (e.g., Bunyavirus) may further mask early infection indicators. Our fluorescent RPA assay, capable of detecting 0.046 parasites/µL—200-fold lower than the current gold standard—directly addresses this vulnerability by intercepting subclinical reservoirs before they enter the blood supply, thereby mitigating a pervasive yet underrecognized threat to transfusion safety. Moreover, malaria has similarities in clinical manifestations with babesiosis, and distinguishing between these two diseases based on clinical microscopic examination alone is challenging28,29. Our specificity evaluation confirmed that the fluorescence RPA method did not amplify samples from P. falciparum or P. ovale infections, demonstrating excellent specificity. This is critical for accurate diagnosis, especially in regions where multiple tick-borne or parasitic diseases coexist, as it reduces the risk of false positives and ensures that patients receive appropriate treatment. Additionally, this ensures that the fluorescence RPA can accurately differentiate between malaria and babesiosis, preventing misdiagnoses and guiding appropriate treatment strategies for these two similar, yet distinct, diseases. We further used the established RPA method to detect B. microti of blood samples collected from 119 patients with fever and thrombocytopenia symptoms in Xinyang City, Henan Province, China30. Both Babesia and Bunyavirus are tick-borne pathogens, but this retrospective study did not collect information on patient tick-bite history. Future studies should gather these data. The study conducted by Seo et al. was conducted to identify the distribution profile of ticks and tick-borne pathogens in Daejeon and the adjacent areas in South Korea, they found Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV, a Bunyavirus) (2 cases), Borrelia spp. (32 cases), and B. microti (7 cases), this indicates that co-infection with SFTSV (a Bunyavirus) and B. microti may occur in regions where both pathogens are endemic.Laboratory diagnostics for patients with fever and thrombocytopenia should consider Babesia infection, particularly when other pathogens like Bunyavirus are not detected31,32. Therefore, in areas where both pathogens circulate, diagnostic workups for febrile patients with thrombocytopenia should include tests for B. microti, especially when tests for Bunyavirus are negative, and should consider the possibility of co-infection in Bunyavirus-positive cases. While recombinase polymerase amplification (RPA) offers rapid and sensitive detection of Babesia spp., several limitations must be acknowledged. First, RPA is prone to false positives due to non-specific amplification in resource-limited settings where contamination risks are higher, as well as false negatives caused by inhibitors in untreated blood samples or extremely low parasitemia levels (< 0.01%) that fall below the assay’s detection threshold19,33. Second, environmental factors such as temperature fluctuations during field testing (optimal RPA requires 37ཞ42°C) and suboptimal sample processing can compromise reproducibility34,35. Third, while RPA can be adapted for multiplex detection, its current capacity to identify co-infections remains limited. Cross-reactivity between primers/probes or dominance of one pathogen’s signal may obscure co-infections, particularly in regions like China where tick-borne pathogens often overlap36. Addressing these challenges requires optimized probe design, rigorous validation of field-deployable protocols, and integration with complementary methods for comprehensive pathogen screening. Conclusion This study established a novel method for detecting B. microti using fluorescent recombinase polymerase amplification (RPA) technology. This method demonstrates high sensitivity, strong specificity, and rapid response, completing DNA amplification and detection in just 20 min. Addition, a retrospective study was conducted to evaluate the application of fluorescence RPA technology for the molecular detection of typical symptoms of babesiosis in the population of Xinyang City, Henan Province, China. Instances of co-infection with Bunyavirus were identified, highlighting the potential of RPA technology to enhance molecular diagnostics in endemic areas. In summary, the RPA method for detecting B. microti shows great promise for field investigations. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements We would like to thank the staff of the National Institute of Parasitic Diseases, the Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research); School of Life Sciences, Fudan University; Department of Biology, College of Life Sciences, Inner Mongolia University, who participated in this study. Appendix A. Supplementary data Supplementary tables 1–3 and supplementary Figs. 1–6 are available online. Author contributions YCC, BX, and WH conceived and designed the experiments; YCC, BX, CHY, KQ and HYY performed the experiments; HYY, ZRM, and SNY analysed the data; YCC, BX, BZ, HYY and WH drafted the manuscript. All authors read and approved the submission of the final manuscript. Funding This study was supported by Shanghai Municipal Science and Technology Commission Special Foundation(24DZ2203100), Science and Technology Leading Talent Team in Inner Mongolia Autonomous Region (2022LJRC0009), the National Parasitic Resources Center, and the Ministry of Science and Technology fund (NPRC-2019-194-30), the National Key Research & Development Program of China (2018ZX10101002-003, 2018ZX10734404), the Three-Year Public Health Action Plan (2023–2025) of Shanghai (No. GWVI-11.2-XD33), Three-Year Initiative Plan for Strengthening Public Health System Construction in Shanghai (2023–2025) Key Discipline Project (No. GWVI-11.1-12). Data availability All data supporting the findings of this study are available within the paper and its Supplementary Information. Declarations Competing interests The authors declare no competing interests. Consent to publish The authors declare that they all agree to publish this paper in this journal. Ethical approval The authors confirmed the study was reported in accordance with ARRIVE guidelines. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yuchun Cai, Han Yin Yang and Kun Qiang contributed equally to this work. Contributor Information Bin Zheng, Email: zhengbin@nipd.chinacdc.cn. Bin Xu, Email: xubin@nipd.chinacdc.cn. Wei Hu, Email: huw@fudan.edu.cn. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data supporting the findings of this study are available within the paper and its Supplementary Information.